Skip to main content

Radiation Innovations for Therapy and Education

Objective

Approximately 45-60% of all cancer patients are treated with radiotherapy. Some of these patients have a good outcome, but in other cases their illness fails to be cured. This may result from distant metastases or from regrowth of the primary tumor. This training network is built on the premise that considerable advances in understanding radiobiology will open novel routes for effective therapeutic intervention with biological targets to improve the outcome of cancer treatment; this progress requires a European-wide effort.
This network of radiobiologists, clinicians and scientists with complementary expertise will stimulate outstanding science, meeting the high demand for excellent young academics enhancing Europe´s competitive capability in this highly relevant but underrepresented and fragmented research area. We will strengthen collaborations and technological platforms to develop effective therapeutic strategies for cancer. The failure to eliminate the primary cancer can be placed into 2 categories: the radioresistance of the tumor and the sensitivity of surrounding normal tissue; and the effects of the tumor microenvironment leading to greater overall resistance and altering the immune response to the tumor. This will be combined with translational work designed to identify and implement new therapeutic strategies for use in radiotherapy. Students will benefit from the expertise of the whole, both academic and industrial including unique research technologies that will now be available throughout the network, including a variety of screening platforms, methodology for preclinical cancer therapy and novel radiation and imaging technologies. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combating a major death-related disease in Europe this project will raise health and bring long-term benefit to the European and international community.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

H2020-MSCA-ITN-2014
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Address
Wellington Square University Offices
OX1 2JD Oxford
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 546 575,76

Participants (5)

UNIVERSITAETSKLINIKUM ESSEN
Germany
EU contribution
€ 498 432,96
Address
Hufelandstrasse 55
45147 Essen
Activity type
Higher or Secondary Education Establishments
UNIVERSITEIT MAASTRICHT
Netherlands
EU contribution
€ 510 748,56
Address
Minderbroedersberg 4-6
6200 MD Maastricht
Activity type
Higher or Secondary Education Establishments
TECHNISCHE UNIVERSITAET DRESDEN
Germany
EU contribution
€ 498 432,96
Address
Helmholtzstrasse 10
01069 Dresden
Activity type
Higher or Secondary Education Establishments
UNIVERSITE CATHOLIQUE DE LOUVAIN
Belgium
EU contribution
€ 501 120
Address
Place De L Universite 1
1348 Louvain La Neuve
Activity type
Higher or Secondary Education Establishments
INSTITUT CURIE
France
EU contribution
€ 525 751,20
Address
Rue D'ulm 26
75231 Paris
Activity type
Research Organisations

Partners (8)

University of Szeged
United States
Address
Massachusetts Avenue 1350
02138 Cambridge
Activity type
Higher or Secondary Education Establishments
PT THERAGNOSTIC BV
Netherlands
Address
Oxfordlaan 55 Biopartner Building
6229 EV Maastricht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EXOMNIS BIOTECH
Netherlands
Address
Oxfordlaan 55
6229 EV Maastricht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Vertex Pharmaceuticals
United Kingdom
Address
86-88 Jubilee Avenue
OX14 4RW Abingdon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MAB Discovery
Germany
Address

Neuried
Activity type
Other
DNA Therapeutics
France
Address

Evry
Activity type
Other
EACR
United Kingdom
Address

Nottingham
Activity type
Other
ESTRO
Belgium
Address

Brussels
Activity type
Other